查詢結果分析
來源資料
頁籤選單縮合
| 題 名 | 低收縮分率心衰竭之最新藥物治療=New Medications for Heart Failure with Reduced Ejection Fraction |
|---|---|
| 作 者 | 蔡玉娟; 陳薏如; 簡素玉; | 書刊名 | 藥學雜誌 |
| 卷 期 | 33:4=133 2017.12[民106.12] |
| 頁 次 | 頁40-45 |
| 分類號 | 415.319 |
| 關鍵詞 | 慢性心衰竭; Valsartan/sacubitril; Ivabradine; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 慢性心衰竭是一個常導致住院並伴隨高死亡率的疾病,血管張力素轉換酶抑制劑 (angiotensin-converting enzyme inhibitor, ACEI)、β-阻斷劑和礦物皮質類固醇受體拮抗 劑等能改善預後,是收縮功能不全心臟衰竭的標準用藥,2016年美國心臟學會心臟衰 竭治療指引納入二個新的藥品-血管張力素受體/腦啡肽酶抑制劑 valsartan/sacubitril 和 心臟節律電流 (If) 抑制劑 ivabradine。由臨床試驗證實 valsartan/sacubitril 可有效減少低 收縮分率心衰竭病人的死亡率和心衰竭住院率,ivabradine 可改善心臟衰竭導致的住院 率,新藥提供心衰竭病人治療的多重選擇。 |
| 英文摘要 | Chronic heart failure is one of the leading causes for hospitalization and accompanied by high mortality. The standardized therapeutic agents for chronic heart failure with reduced ejection fraction, including beta blockers, angiotensin converting enzyme inhibitors, and aldosterone antagonists have shown beneficial outcomes. 2016 the American college of cardiology focused update on two newly pharmacological therapies: the combined angiotensin-receptor/neprilysin inhibitor valsartan/sacubitril and cardiac pacemaker current (If) inhibitor ivabradine for heart failure. In clinical trials, valsartan/sacubitril has demonstrated benefit in reducing mortality and HF-related hospitalization for patients with HFrEF, and ivabradine has proven efficacious in HF-related hospitalization. They provide more pharmacotherapy options in HF. |
本系統中英文摘要資訊取自各篇刊載內容。